Fractyl Health, Inc. Common Stock
NASDAQ:GUTSBiotechnology
-$0.01 today
- Market cap
- $55.18M
- Beta
- 2.34
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.42
Volume 0.10M
Average 2.07M
GUTS Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Fractyl Health, Inc. Common StockNASDAQ: GUTS
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 75.82M shares rose 55.2% year over year, ahead of the +37.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +16.8% a year.
Context
- Weighted avg shares increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +55.2% holds above the trailing-twelve-month pace of +37.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 75.82M USD
- Year-over-year change
- +74.1%
- 4-year CAGR
- +12.3%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 75.82M | +74.1% |
| FY2024 | 2024-12-31 | 43.54M | -8.5% |
| FY2023 | 2023-12-31 | 47.61M | +0.0% |
| FY2022 | 2022-12-31 | 47.61M | +0.0% |
| FY2021 | 2021-12-31 | 47.61M | — |
Weighted Avg Shares vs competitors
How GUTS compares with its peers on the latest reported figures
- GUTS's LTM Mar 2026 weighted avg shares of 66.33M shares is the 2nd highest of the 7 companies compared; the peer median is 39.2M shares.
- Its year-over-year change of +37.1% is the 3rd highest of 7, against a peer median of +11.6%.
- Over three fiscal years its annual growth of +16.8% compares with a peer median of +20.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 95.83M | +20.8% | +48.5% | |
| LTM Mar 2026 | 66.33M | +37.1% | +16.8% | |
| LTM Mar 2026 | 56.46M | +55.6% | +21.3% | |
| LTM Mar 2026 | 53.9M | +2.3% | +9.7% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | 24.5M | +1.8% | +11.6% |
| LTM Mar 2026 | 12.13M | +61.6% | +63.6% | |
| LTM Mar 2026 | 6.42M | -22.0% | +18.8% | |
| Peer median (excluding GUTS) | 39.2M | +11.6% | +20.0% | |
Competitors are the stored peer set for GUTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 120K | 93K | 0 |
| Cost of Revenue | 0 | 452K | 77K | 50K | 0 |
| Gross Profit | 0 | (452K) | 43K | 43K | 0 |
| Gross Margin | — | — | 35.8% | 46.2% | — |
| Research & Development | 26.44M | 34.35M | 38.04M | 70.47M | 74.54M |
| Selling, General & Admin | 10.49M | 14.58M | 0 | 0 | 22.28M |
| Operating Expenses | 36.93M | 48.93M | 50.88M | 93.57M | 96.82M |
| Depreciation & Amortization | 676K | 452K | 286K | 677K | 1.13M |
| EBITDA | (36.62M) | (46M) | (76.81M) | (68.02M) | (139.83M) |
| EBITDA Margin | — | — | -64004.2% | -73136.6% | — |
| Operating Income | (36.93M) | (49.39M) | (50.84M) | (93.53M) | (96.82M) |
| Operating Margin | — | — | -42363.3% | -100571.0% | — |
| Interest Income | 0 | 797K | 1.26M | 4.15M | 1.54M |
| Interest Expense | 1.44M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.81M) | 2.93M | (26.26M) | 24.84M | (44.14M) |
| Income Before Tax | (38.74M) | (46.45M) | (77.09M) | (68.69M) | (140.95M) |
| Pre-Tax Margin | — | — | -64242.5% | -73864.5% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (38.74M) | (46.45M) | (77.09M) | (68.69M) | (140.95M) |
| Net Margin | — | — | -64242.5% | -73864.5% | — |
| EPS (Basic) | (1.12) | (1.34) | (1.98) | (1.62) | (1.86) |
| EPS (Diluted) | (1.12) | (1.34) | (1.98) | (1.62) | (1.86) |
| Weighted Avg Shares | 47.61M | 47.61M | 47.61M | 43.54M | 75.82M |
| Weighted Avg Shares (Diluted) | 47.61M | 47.61M | 47.61M | 43.54M | 75.82M |
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
Intrinsic Alpha fair value
Locked
Current Price
$4.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.